Who
Sue-Jean Lin
Director
Company insider
Files Form 4 as: Director, Arcutis Biotherapeutics; Director, Stevanato Group S.p.A.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.0M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 9 Jun 2021
- Last trade
- 15 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $121K4,946 at $24.38 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $121K4,946 at $24.38 | filing |
| 12 Jun 2026filed 26 Jun 2026 | STVN Stevanato Group S.p.AMedical Devices | SEC FORM 4 Code A | —4,975 at $0.00 | filing |
| 12 Jun 2026filed 26 Jun 2026 | STVN Stevanato Group S.p.AMedical Devices | SEC FORM 4 Code A | —4,975 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 24 Nov 2025filed 25 Nov 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,052 at $0.00 | filing |
| 24 Nov 2025filed 25 Nov 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,220 at $0.00 | filing |
| 24 Nov 2025filed 25 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $156K18,052 at $8.63 | filing |
| 24 Nov 2025filed 25 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $54K7,220 at $7.51 | filing |
| 24 Nov 2025filed 25 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $778K25,272 at $30.78 | filing |
| 12 Jun 2025filed 16 Jun 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,568 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —7,609 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,052 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —10,139 at $0.00 | filing |
| 31 May 2023filed 2 Jun 2023 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,220 at $0.00 | filing |
| 31 May 2023filed 2 Jun 2023 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —4,375 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,796 at $0.00 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Sue-Jean Lin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.